NPM1 and acute myeloid leukemia: Moreover, the compound showed higher efficacyin patients with NPM1 C+ AML (IC50 = 1.725 μM, n = 4) than in WT NPM1 AML patients (IC50 = 3.774μM, n = 3, p-value ≤0.007)(Figure 5B).